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haor@public3.bta.Abstract Human xenograft mouse models, which have been used in cancer research for over a
century, provided signiﬁcant advances for our understanding of this multifaceted family of diseases.
Orthotopic transplantation tumor models are emerging as the preference for cancer research due to
the increasing clinical relevance over subcutaneous mouse models. In this study, a stable luciferase-
expressed Capan-2 cell line was constructed and the expression of luciferase was tested. The results
showed that the luminorescence intensity of Capan-2Luc cells was associated with the number of
cells and the minimal detectable cell population was 600 cells/well. We established an orthotopic
transplantation model of pancreatic cancer using Capan-2Luc cell line in athymic mice and
investigated the inhibitory effects of gemcitabine (Gem) in vitro and in vivo. Optical imaging system
was applied to evaluate the tumor growth of orthotopic transplantation model in vivo. The resultsedica, Chinese Academy of Medical Sciences and Chinese Pharmaceutical Association. Production and
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In vivo real-time imaging of gemcitabine-leaded growth inhibition 221suggested that the orthotopic transplantation model of pancreatic cancer was well established and
the luminorescence intensity of Gem-treated group was markedly lower than that of control group
with an inhibitory rate of 56.8% (Po0.001). Our orthotopic transplantation model of pancreatic
cancer and real-time imaging observation method established in this study could be an ideal model
and a useful tool for therapeutic approaches for pancreatic cancers.
& 2011 Institute of Materia Medica, Chinese Academy of Medical Sciences and Chinese Pharmaceutical
Association. Production and hosting by Elsevier B.V. All rights reserved.1. Introduction
Pancreatic cancer is one of the most lethal cancers, which is
incidence of occult, high grade, and has extremely poor prog-
nosis1. There are great needs to develop advanced models for the
preclinical investigation of pancreatic cancer. It is estimated that
43,140 people (21,370 men and 21,770 women) will be diagnosed
with cancer of the pancreas in 2010, and that 36,800 men and
women will die of this disease2. The use of orthotopic transplanta-
tion pancreatic tumor models for preclinical research reproduces
its pattern of local growth and distal dissemination. It may
improve the development of therapeutic strategies and diagnostic
imaging modalities against this disease. Optical imaging system is
a new tool which can observe tumor growth, metastasis, and other
biological processes in vivo3. When tumor cells express luciferase,
the optical imaging system using Living Image- software (Xeno-
gen) can directly track the process of tumor growth in situ4.
No effective early diagnosis of pancreatic cancer is available
and progress in development of treatment is slow. Chemother-
apy is one of the most common treatments for pancreatic
cancer and Gemcitabine (Gem) is one important chemother-
apy drug for this disease. Since Gemcitabine can signiﬁcantly
prolong survival time and improve the clinical beneﬁt rate, US
Food and Drug Administration approved Gemcitabine as the
ﬁrst-line drug for pancreatic cancer chemotherapy in 19985.
However, the beneﬁt of Gemcitabine monotherapy in
advanced and metastatic pancreatic cancer is limited6.
In this study, an engineering modiﬁed human pancreatic
cancer cell Capan-2Luc was used to develop luciferase labeled
orthotopic transplantation pancreatic cancer model. The anti-
tumor effect of Gemcitabine on pancreatic cancer in situ was
observed. We suppose that this animal model can provide an
ideal preclinical tool for evaluating anti-pancreatic cancer drugs.2. Materials and methods
2.1. Cell culture and reagents
Human pancreatic cancer Capan-2 cells were purchased from
ATCC (ATCC HTB-80) and routinely grown in RPMI-1640
(Hyclone, Utah) supplemented with 10% FBS (Gibco, USA),
penicillin-streptomycin (1%), and 2 mmol/L L-glutamine.
Gem was from Eli Lilly (USA). D-luciferin was purchased
from Xenogen (Alameda, CA).
2.2. MTT assays
Capan-2 cells were seeded in 96-well plates at a density of
3 103 cells/well in 200 mL medium. Then the cells were treatedwith various concentrations of Gem. After drug exposure for
48 h, the MTT solution (5 g/L) was added to the plates. The
cells were incubated at 37 1C for another 4 h. The formazan,
which is derived from MTT by living cells, was dissolved in
150 mL DMSO per well, and the absorbance was detected
at 570 nm. All MTT experiments were performed in triplicate
and repeated at least 3 times. The percentage of cytotoxicity
was calculated as follows: cytotoxicity (%)¼(1OD570 of
experimental well)/OD570 of control well. The IC50 (deﬁned as
the drug concentration at which 50% cell growth was inhibited)
was assessed from the dose–response curves.
2.3. Transfection and selection of stably transfected
Capan-2Luc cells
Capan-2 cells at 70–80% conﬂuence density were transfected
with 1 mg of luciferase expression plasmid PCAGGS-NEO-luc
using Lipofectamine 2000 (Invitrogen, Carlsbad, CA) accord-
ing to the manufacturer’s instructions. For stable expression,
the cells were exposed to 500 mg/mL G418 (Gibco, USA) after
1 day transfection. After growth for 3 weeks, cells were plated
at a lower density in MEM with 500 mg/mL G418 and 10%
FBS in 96-wells plates until single colony was formed. Single
cloned cells were isolated and expanded. To identify the
positive clones, monoclonal cells were plated in 96-well plates
and luciferase substrate D-luciferin was added to a ﬁnal
concentration of 60 mg/mL. After 30 min of exposing with
the optical imaging system (IVIS200, Xenogen), ﬂuorescence
intensity of expression was tested, and the most ﬂuorescent
clone was selected and cryopreserved.
2.4. Luciferase activity test of Capan-2Luc in vitro
The Capan-2Luc cells were diluted in 96-well plates at a density
of 5000, 2500, 1250, 600, 300, 150, 75 and 0 cells per well in the
presence of ﬂuorescent luciferase substrate D-luciferin. The
luminous intensity was detected in the camera box.
2.5. Establishment of orthotopic transplantation human
pancreatic tumor model
The 6–8 week-old female athymic nude mice (BALB/c, nu/nu)
were purchased from the Institute for Experimental Animals,
Chinese Academy of Medical Sciences & Peking Union
Medical College (Beijing, China). The study was proceeded
in accordance with the regulations of Good Laboratory
Practice for non-clinical laboratory studies of drugs issued
by the National Scientiﬁc and Technologic Committee of
People’s Republic of China. Human pancreatic cancer cells
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cells/mL with RPMI-1640 medium. Nude mice were anesthe-
tized with injection of 60 mg/mL pentobarbital sodium intra-
peritoneally, and following by making a small incision into the
abdomen along the lower left rib cage to pull out the pancreas
and inject 3 105/0.02 mL of Capan-2Luc cell suspension into
it. Incision suture was operated according to conventional
surgery. At 15, 30, 45, 60 days after surgery, luciferase
substrate D-luciferin (150 mg/kg) was injected intraperitone-
ally, and the animals were placed onto the warmed stage inside
the camera box (IVIS-Imaging System, Xenogen) to observe
tumor growth7. After 60 days, all mice were weighed and
sacriﬁced, and the tumors were excised. In addition, pancreatic
tissues were taken from ﬁve nude mice on day 15 for HE
staining after formalin-ﬁxiation and parafﬁn-embedding.Figure 1 Analysis of Gem-leaded growth inhibition in Capan-
2Luc cells. Cells were treated by various concentrations of Gem for
24 h, and then were determined by MTT assay.2.6. In vivo experiment
Nude mice were injected with 3 105 Capan-2Luc cells as
described. On day 15 after inoculation, the animals were
randomized into two groups (n¼7 per group): control group
(saline) and Gem (80 mg/kg) treatment group. The mice were
injected with either saline or Gem intravenously, once a week
for two weeks. All mice were weighed and sacriﬁced, and the
tumors were excised and weighed by the end of experiment,
which was 60 days after tumor inoculation.Figure 2 The positive correlation between the photons of
bioluminescence and the numbers of Capan-2Luc cells. Cell
photons were determined by IVIS-Imaging System.2.7. Statistics
Data were described as means7SD of the indicated number of
individual experiments. A one-way analysis of variance was
carried out for multiple comparisons. If there was signiﬁcant
variation between treatment and control groups, the mean
values were compared using Student’s t-test. P-values less than
0.05 were considered statistically signiﬁcant difference.3. Results
3.1. Inhibitory effect of Gem on human pancreatic cancer
Capan-2Luc cells
To investigate the antitumor effect of Gem on Capan-2Luc
cells in vitro, cells were incubated with various concentrations
of Gem for 48 h. After drug exposure, cell proliferation was
determined by MTT assay. The results showed that Gem
could inhibit the proliferation of human pancreatic cancer
Capan-2Luc cells in a dose-dependent manner (Fig. 1), and
IC50 was 1.01 107 mol/L.3.2. Luciferase activity in Capan-2Luc cells
Since Capan-2Luc cells can express luciferase, its activity was
detected using optical imaging system in the presence of
D-luciferin. When various numbers of cells were seeded in
the plate, various luminescence intensities were detected by
IVIS-Imaging System. The bioluminescence photon was posi-
tively correlated to the number of cells. The minimum
detectable cell number was 600 cells per well according to
our results (Fig. 2).3.3. Optical imaging in living animal
In order to observe the real-time growth of tumors in situ,
optical imaging system was used to track the tumor growth.
On day 15 after tumor inoculation, bioluminescence in
pancreas of the nude mice could be detected, indicating that
Capan-2Luc cells successfully grown in the pancreas (Fig. 3A).
The ﬂuorescence intensity of the pancreas in situ increased
signiﬁcantly from day 15 to day 60, suggesting that the
transplanted tumor has been established and gradually grown.
However, there was no convincing metastasis being observed.
The amount of bioluminescence photon showed signiﬁcant
difference between control group and Gem treatment group
from day 30 to day 60 (Po0.001). The growth curve of
photons emitted by Capan-2Luc cells against tumor-bearing
time of mice showed the proliferation of luciferase labeled
Capan-2Luc cells in nude mice (Fig. 3B). The results showed
that Gem signiﬁcantly inhibited tumor growth.
3.4. Gem inhibited Capan-2Luc cells orthotopic transplantation
pancreatic tumor growth
On day 60 after orthotopic transplantation, animals were
sacriﬁced and the tumor were excised and weighed. The results
Figure 3 Gem-mediated growth inhibitions of orthotopic transplantation tumor of human pancreatic Capan-2Luc cells. (A) The proﬁle
of optical imaging. (B) The growth curve of pancreas tumor.
Table 1 The inhibitory effect of Gem on orthotopic
transplantation tumor of human pancreatic Capan-2Luc cells.
Drug Dose (mg/kg) Tumor weight (g) Inhibition
(%)
Control – 0.3770.09 –
Gem 80 0.1670.03n 56.8
Administration at day 7 and day 15 (iv) and detection at day 60
after tumor transplantation; n¼7
nPo0.001, compared with control.
Table 2 The weight changes of various treated tumor-
bearing mice (n¼7).
Group Body weight (g) Change of body
weight (g)
Begin End
Control 20.4770.91 19.4571.07 1.0270.05
80 mg/kg
Gem
19.8770.81 19.3170.79 0.5670.04n
nPo0.05, compared with control.
Figure 4 The proﬁle of various treated orthotopic transplanta-
tion tumor of human pancreatic Capan-2Luc cells.
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was signiﬁcantly inhibited by Gem (80 mg/kg) with the
inhibition rate of 56.8% (Po0.001) (Table 1). The two groups’
mice body weight exhibits signiﬁcant difference: Gem-treated
group mildly increased while control group decreased
(Po0.05) (Table 2). This indicated that the tumor affected
mice growth by pancreatic function loss. As shown in Fig. 4,
deep-colored tissue was spleen and light-colored tissue was
pancreatic tumor. Compared to control group, the pancreatic
tumors in Gem-treated group were smaller, which correlated
with data from image system. Spleen tissues were normal,
indicating Gem at the dosage used in this study was non-toxic
to spleen.
Figure 5 The pathological changes of orthotopic transplantation tumor of human pancreatic Capan-2Luc cells by HE staining. Light
microscope ( 200). (A) The tumor cells grew nodularly, arranged in solid and nested architecture. (B) Tumor cells were polygonal
conformation with clear boundary and large round nuclei, heteromorphism and mitotic phase.
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transplantation pancreatic cancer
HE staining results showed the tumor cells in pancreatic tissue
were polygonal conformation with clear boundary and large
round nuclei, heteromorphism and mitotic phase (Fig. 5B). In
addition, the tumor cells grew nodularly, arranged in solid and
nested architecture. Meanwhile, small blood sinus and rarely
gland-like structure were in line with poorly differentiated
pancreatic carcinoma comparing to normal tissue (Fig. 5).4. Discussion
In recent years, the incidence of pancreatic cancer was rising
and was still an important unsolved health problem in the
world. It was estimated that pancreatic cancer acted as the
seventh or eighth cause of cancer death in China, and fourth
lethal human cancer in the United States. As the growth of
pancreatic cancer, it was easy to inﬁltrate into pancreas
surrounding tissues and blood vessels, and developed lymph
node metastasis. Almost 100% of patients with pancreatic
cancer develop metastases and die of the debilitating metabolic
effects of their unrestrained growth8. In addition, pancreatic
cancer could directly invade perineurium space and spread
along the nerve bundle.
Gem is a deoxycytidine analog with structural and meta-
bolic similarities to cytarabine. Gem must be phosphorylated
to its active metabolites: Gem diphosphate and Gem tripho-
sphate. Gem diphosphate inhibits ribonucleotide reductase
and depletes intracellular pools of all the deoxynucleotide
triphosphates necessary for DNA synthesis. Gem triphosphate
may be incorporated into an elongating DNA chain and leads
to premature chain termination which may lead to apoptosis9.
Although Gem is currently the ﬁrst choice chemotherapy drug
for pancreatic cancer, its efﬁcacy is not inspiring, only
about 20%.
Despite many efforts made in the past decades, pancreatic
cancer is resistant to currently available conventional treat-
ment approaches, such as surgery, radiation, chemotherapy,
or combination therapies. Therefore, new drugs discovery to
multiple and comprehensive treatments are highly neces-
sary10,11. The establishment of appropriate animal models of
pancreatic cancer could improve the development of therapies
and drugs discovery against this disease. Heterotopicsubcutaneous models are implanted between the dermis and
underlying muscle, and are typically located on the ﬂank, on
the back or the footpad of the mouse. For over 30 years, the
subcutaneous xenograft model has been the most widely used
preclinical mouse model for cancer research. It is rapid,
inexpensive, easily reproducible. Subcutaneous model could
also provide visual conﬁrmation that mice used in an experi-
ment have tumors prior to therapy, and provide a means of
assessing tumor response or growth over time12.
However, a major disadvantage of subcutaneous xenograft
models is that are curative in mouse subcutaneous xenograft
models often do not have a signiﬁcant effect on human
disease. The primary cause of this failure may be due to the
observation that the subcutaneous microenvironment is not
relevant to that of the organ site of primary or metastatic
disease. These observations suggest that heterotopic tumor
models do not represent appropriate sites for human
tumors13,14. Advantages of orthotopic tumor models include
use of the relevant site for tumor–host interactions, the
emergence of disease-relevant metastases, the ability to study
site-speciﬁc dependence of therapy, organ-speciﬁc expression
of genes and that clinical scenarios can be replicated, e.g.
surgical removal of primary tumor, or adjuvant therapy of
occult metastasis13. Therefore, orthotopic human pancreatic
cancer xenografts models are used as the preference for cancer
research due to the increased clinical relevance and similar to
the ideal of the ‘‘anthropomorphic’’ (patient-like) pancreatic
cancer model15.
We have established a luciferase labeled orthotopic trans-
plantation human pancreatic cancer model in athymic nude
mice. Furthermore, we used the optical imaging system
(IVIS200, Xenogen) to observe the growth of Capan-2Luc cells
in live animals and track the process of the animal construc-
tion. The current model overcomes the deﬁciencies of the
traditional animal model, in which was difﬁcult to observe
in vivo dynamic process of tumor growth, invasion and
metastasis.5. Conclusions
For the ﬁrst time, a human pancreatic cancer Capan-2Luc cells
orthotopic transplantation xenograft model was successfully
established in nude mice in this study. This orthotopic
xenograft pancreatic tumor model has several advantages,
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ogy, etc. In this human pancreatic cancer orthotopic trans-
plantation xenograft model, the efﬁcacy of Gem was evaluated
using optical imaging system to real-time observe the inhibi-
tory effect of the drug, and the results were consistent with
clinical treatment, which indicated that this in vivo model is a
convincing evaluation model, which could accelerate preclini-
cal investigation of new therapies and drugs against pancreatic
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